Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.

The present invention relates to a composition, preferably a cosmetic composition, comprising, in an aqueous phase: at least one anti-acne active agent; and hydroxyethylcellulose and at least poly(2-acrylamido 2-methyl propane sulfonic acid),
and uses thereof.

The present invention relates to a composition, preferably a cosmetic composition, comprising, in an aqueous phase: at least one anti-acne active agent; and hydroxyethylcellulose and at least poly(2-acrylamido 2-methyl propane sulfonic acid),
and uses thereof.

The present disclosure provides a pharmaceutical composition comprising H1 antagonist or a salt or a hydrate or a solvate thereof: a diluent; a solvent; an emollient; a humectant; a preservative; an emulsifier; and a surfactant, said composition being formulated as a topical formulation. The composition may include one or more additional active agents. The composition is formulated into a topical lotion, solution, spray, emulsion, emulsion of water and oil (oil in water or water in oil emulsion), gel, or cream. The compositions of the present disclosure may find utility in treatment of allergic conditions/diseases of skin. It further relates to a method of treating an allergic condition using the compositions of the present disclosure.

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

A porous carbon material composite formed of a porous carbon material and a functional material and equipped with high functionality. The porous carbon material composite is formed of (A) a porous carbon material obtainable from a plant-derived material having a silicon (Si) content of 5 wt % or higher as a raw material; and (B) a functional material adhered on the porous carbon material, and has a specific surface area of 10 m.sup.2/g or greater as determined by the nitrogen BET method and a pore volume of 0.1 cm.sup.3/g or greater as determined by the BJH method and MP method.

A porous carbon material composite formed of a porous carbon material and a functional material and equipped with high functionality. The porous carbon material composite is formed of (A) a porous carbon material obtainable from a plant-derived material having a silicon (Si) content of 5 wt % or higher as a raw material; and (B) a functional material adhered on the porous carbon material, and has a specific surface area of 10 m.sup.2/g or greater as determined by the nitrogen BET method and a pore volume of 0.1 cm.sup.3/g or greater as determined by the BJH method and MP method.

A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

A topical ophthalmological composition includes a multikinase inhibitor as an active pharmaceutical ingredient, and perfluorohexyloctane (F6H8) as a liquid vehicle. The multikinase inhibitor inhibits vascular endothelial growth factor receptors (VEGFRs). A method for treating an ophthalmological disorder includes: providing a topical ophthalmological composition containing a multikinase inhibitor at a concentration of about 0.01-10% (w/v); and treating a patient with the topical ophthalmological composition for treating the ophthalmological disorder.

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.